Feasibility of engineered Bacillus subtilis for use as a microbiome‐based topical drug delivery platform
Bioengineering & Translational Medicine · 2024-07 · 9 (4)
DOI: 10.1002/btm2.10645 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioengineering & Translational Medicine, online erschienen am 02.01.2024. Verfasst von Veronica A Montgomery und 3 weiteren Autor:innen. Beteiligte Einrichtung: Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Tech Georgia Institute of Technology Atlanta Georgia USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIBIB NIH HHS, American Association of University Women, Tau Beta Pi.
Abstract (Originalsprache)
Non‐adherence to medication is a major challenge in healthcare that results in worsened treatment outcomes for patients. Reducing the frequency of required administrations could improve adherence but is challenging for topical drug delivery due to the generally short residence time of topical formulations on the skin. In this study, we sought to determine the feasibility of developing a microbiome‐based, long‐acting, topical delivery platform using Bacillus subtilis for drug production and delivery on the skin, which was assessed using green fluorescent protein as a model heterologous protein for delivery. We developed a computational model of bacteria population dynamics on the skin and used its qualitative predictions to guide experimental design choices. Using an ex vivo pig skin model and a human skin tissue culture model, we saw persistence of delivered bacteria for multiple days and observed little evidence of cytotoxicity to human keratinocyte cells in vitro . Finally, using an in vivo mouse model, we found that the delivered bacteria persisted on the skin for at least 1 day during every‐other‐day application and did not appear to present safety concerns. Taken together, our results support the feasibility of using engineered B. subtilis for topical drug delivery.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Tech Georgia Institute of Technology Atlanta Georgia USA.
- School of Chemical and Biomolecular Engineering Georgia Institute of Technology Atlanta Georgia USA.
ORCID-Profile: Veronica A Montgomery, Amy J Wood-Yang, Mark P Styczynski, Mark R Prausnitz
Förderung
- NIBIB NIH HHS
- American Association of University Women
- Tau Beta Pi
- National Science Foundation
Zitieren
APA
Montgomery, V. A., Wood-Yang, A. J., Styczynski, M. P., & Prausnitz, M. R. (2024). Feasibility of engineered Bacillus subtilis for use as a microbiome‐based topical drug delivery platform. Bioengineering & Translational Medicine, 9(4). https://doi.org/10.1002/btm2.10645
Vancouver
Montgomery VA, Wood-Yang AJ, Styczynski MP, Prausnitz MR. Feasibility of engineered Bacillus subtilis for use as a microbiome‐based topical drug delivery platform. Bioengineering & Translational Medicine. 2024;9(4). doi:10.1002/btm2.10645
BibTeX
@article{Montgomery2024,
author = {Montgomery, Veronica A and Wood-Yang, Amy J and Styczynski, Mark P and Prausnitz, Mark R},
title = {Feasibility of engineered Bacillus subtilis for use as a microbiome‐based topical drug delivery platform},
journal = {Bioengineering & Translational Medicine},
year = {2024},
volume = {9},
number = {4},
doi = {10.1002/btm2.10645}
}
EUVIMED